Geniposidic acid

製品コードS2413 バッチS241301

印刷

化学情報

Synonyms

N/A

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₁₆H₂₂O₁₀

分子量

374.34

CAS No.

27741-01-1

Solubility (25°C)*

体外

DMSO

16 mg/mL (42.74 mM)

Ethanol

2 mg/mL (5.34 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Geniposidic acidは、炎症、黄疸、肝疾患の治療に使用されるイリドイド配糖体です。
in vivo	Geniposidic acid shows a more remarkable inhibitory activity factor against implanted tumor growth when the doses of 500 mg/kg are given alone or combined with irradiation. Geniposidic acid improves the plaque area, intima/media thickness ratio, and intimal foam cells number in rabbits. Geniposidic acid (100 μg/mL) results in relieving ECs shedding and improving aortic morphology disorders in rabbits. Geniposidic acid (100 μg/mL) performs significant inhibition on smooth muscle cells proliferation in rabbits. Geniposidic acid results in obvious inhibition on SMC migration from the upper chamber. Geniposidic acid increases survival rate of rats with fulminant hepatic failure. Geniposidic acid attenuates the following effects: GalN/LPS increases serum aminotransferase activity, serum tumor necrosis factor-α level and hepatic lipid peroxidation and decreases hepatic glutathione content. Geniposidic acid augmentes increases in serum interleukin-6 level, heme oxygenase-1 and NF-E2-related factor 2 protein expression in rats with fulminant hepatic failure. Geniposidic acid decreases cleaved caspase-8 and caspase-3 protein expression and shows significantly fewer apoptotic cells in rats with fulminant hepatic failure. Geniposidic acid increases Bcl-xL protein expression and decreased Bax protein expression in rats with fulminant hepatic failure. Geniposidic acid treatment enhances phosphorylation of signal transducer and activator of transcription 3 in rats with fulminant hepatic failure.

製品説明

Geniposidic acidは、炎症、黄疸、肝疾患の治療に使用されるイリドイド配糖体です。

in vivo

Geniposidic acid shows a more remarkable inhibitory activity factor against implanted tumor growth when the doses of 500 mg/kg are given alone or combined with irradiation. Geniposidic acid improves the plaque area, intima/media thickness ratio, and intimal foam cells number in rabbits. Geniposidic acid (100 μg/mL) results in relieving ECs shedding and improving aortic morphology disorders in rabbits. Geniposidic acid (100 μg/mL) performs significant inhibition on smooth muscle cells proliferation in rabbits. Geniposidic acid results in obvious inhibition on SMC migration from the upper chamber. Geniposidic acid increases survival rate of rats with fulminant hepatic failure. Geniposidic acid attenuates the following effects: GalN/LPS increases serum aminotransferase activity, serum tumor necrosis factor-α level and hepatic lipid peroxidation and decreases hepatic glutathione content. Geniposidic acid augmentes increases in serum interleukin-6 level, heme oxygenase-1 and NF-E2-related factor 2 protein expression in rats with fulminant hepatic failure. Geniposidic acid decreases cleaved caspase-8 and caspase-3 protein expression and shows significantly fewer apoptotic cells in rats with fulminant hepatic failure. Geniposidic acid increases Bcl-xL protein expression and decreased Bax protein expression in rats with fulminant hepatic failure. Geniposidic acid treatment enhances phosphorylation of signal transducer and activator of transcription 3 in rats with fulminant hepatic failure.

プロトコル(参考用のみ)

参考

https://pubmed.ncbi.nlm.nih.gov/9065798/
https://pubmed.ncbi.nlm.nih.gov/24963945/
https://pubmed.ncbi.nlm.nih.gov/23298456/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei [ J Pers Med, 2022, 12(2)258]	PubMed: 35207746
Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome [ Hum Cell, 2022, 10.1007/s13577-022-00671-y]	PubMed: 35118583
Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone [ Hum Cell, 2021, 10.1007/s13577-021-00639-4]	PubMed: 34731453
Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma [ Hum Cell, 2021, 34(6):1911-1918]	PubMed: 34383271
Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone [ Hum Cell, 2021, 10.1007/s13577-021-00579-z]	PubMed: 34304386
Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors. [ Cancer Cell Int, 2020, 19;20:58]	PubMed: 32099531
Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor [ Hum Cell, 2020, 10.1007/s13577-020-00425-8]	PubMed: 32886306
Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma [ Hum Cell, 2020, 10.1007/s13577-020-00420-z]	PubMed: 32870449

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。